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Abstract
Valuable knowledge about schizophrenia has been recently generated for deciphering its pathobiology and revealing biomarkers. However, efforts are still needed, 
especially if we take in account that this debilitating mental disorder affects approximately 30 million people worldwide. Considering that schizophrenia is a result 
of a complex interaction among environmental factors altered gene function and systematic differential protein expression, proteomics is likely to be a suitable 
tool for studying this disorder. Here we synthetize the main findings by proteomic studies and further directions to be taken in order to better comprehend the 
biochemistry of schizophrenia as well as reveal biomarkers. In addition, we summarize proteomic methodologies used in such studies. 
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Resumo
Valioso conhecimento a respeito de esquizofrenia tem sido gerado recentemente para decifrar sua patobiologia e revelar biomarcadores. Entretanto, esforços 
ainda são necessários, especialmente se levarmos em conta que essa debilitante desordem mental afeta aproximadamente 30 milhões de pessoas ao redor do 
mundo. Considerando que esquizofrenia é resultado de uma complexa interação entre fatores ambientais, função genética alterada e expressão proteica diferencial 
sistemática, a proteômica é provavelmente uma ferramenta adequada ao estudo dessa desordem. Aqui sintetizamos os principais achados em estudos proteômicos 
e posteriores direções a serem tomadas de forma a melhor compreender a bioquímica da esquizofrenia, bem como revelar biomarcadores. 
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Introduction
Proteomics is a relatively new science which has been used for un-
derstanding and identifying affected molecular pathways providing 
a picture of integrated biochemical systems as well as potential 
biomarker candidates. Considering that the development and 
progression of schizophrenia (SCZ) – a chronic mental disorder 
which may affect up to 1% of the world population – is likely to be 
triggered by an intricate interaction among genetic predisposition, 
environmental factors and altered gene and protein expression, 
proteomics is consequently a suitable tool for unraveling SCZ mo-
lecular alterations and identifying biomarkers. Post-mortem and in 
vivo tissue such as brain, cerebrospinal fluid (CSF), liver, fibroblasts 
and blood serum collected from SCZ patients have been investigated 
extensively in the past 10 years using proteomic methodologies, 
which are summarized below1. 
Main outcomes
Brain, CSF and neuroendocrine system
Brain regions as frontal cortex, dorsolateral prefrontal cortex, anterior 
temporal lobe, anterior cingulate cortex, corpus callosum, insular 
cortex, posterior superior temporal gyrus, thalamus and hippocam-
pus have been studied by proteomics. Alterations in cytoskeleton 
architecture through the differential expression of proteins such as 
GFAP, NEFL, NEFM, DNM1 and TUBB are supported by the diffe-
rences observed in these brains when compared to mentally healthy 
controls2. The differential expression of these proteins may interfere 
in several processes, from cellular structure and communication up 
to synaptic transmission, which may also be disturbed due to the 
differential expression of calcium-related proteins such as CALN 
(PPP3CA), CALM and PMCA-43. Calcium is an essential metabolite 
for the dopamine hypothesis in SCZ, especially considering its crucial 
role in the function of dopamine receptors D1 and D24.
Several proteomic differences observed in postmortem brain 
tissue revealed proteins related to oligodendrocytes5. Interestingly, 
these were also found in previous transcriptomic studies6,7. Le-
vels of MBP and MOG, classical multiple sclerosis markers, were 
found altered in the CSF of SCZ patients compared to controls8 
suggesting potential degenerative processes even if not the clas-
sical neurodegeneration. In addition, the hypothesis of disturbed 
metabolism of cholesterol and phospholipids in SCZ is supported 
by proteomics data in CSF studies by the differential expression of 
APOE, APOA1 and PTGDS9,10. Furthermore, neurodegenerative 
processes may be triggered by dysfunction of energy metabolism 
in oligodendrocytes11.
Consistent differences across the different brain regions analyzed 
were also observed in energy metabolism-related proteins supporting 
the “hypofrontality” concept, and reduced blood flow in some regions 
of the brain12-14. The consistent differential expression of ALDOC, 
ENO2, HK1, PGAM1, TPI1 and GAPDH place Glycolysis as one of 
the main biochemical pathway for further studies, basic or clinical. 
Interestingly, this is not the most affected pathway found in the pre-
frontal cortex of depression brains but oxidative phosphorylation15. 
Differences in energy metabolism found in the brain were also 
observed in liver samples in a proteome comparison study analy-
zing 15 livers from SCZ patients and 15 controls. Oxidative stress 
proteins have also been found16. This study is particularly interesting 
considering that the liver releases many molecules directly into the 
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bloodstream that can be indicative of altered metabolism and could 
be used to translate brain findings to peripheral tissues. Proteome 
analyses of pituitaries from patients and controls also revealed energy 
metabolism impairments such as differential expression of AVP and 
GLUT1 which are responsible to control circulating glucose levels17. 
Additionally, apolipoproteins, as in CSF, were found differentially 
expressed in pituitaries. 
Serum and skin fibroblasts
As means to translate CNS findings to the periphery, skin fibroblast 
may be an interesting sample of choice since many molecular path-
ways are shared with neuronal cells. Skin fibroblasts can be biopsied 
from living patients and can also be used as a source of biomarkers. 
Using label-free proteomics, the proteomes of 12 SCZ patients were 
compared to 12 controls leading to the identification of cell cycle 
proteins as well as energy metabolism and oxidative18. 
Blood is the most easily accessible tissue for clinical studies. 
While findings in CNS and liver are useful for the comprehension 
of the molecular bases of SCZ, studies in blood serum can yield po-
tential biomarkers for clinical use as for diagnosis, prognosis, patient 
stratification and studies of drug treatment response.
Ten proteins were found differentially expressed in a set of 55 
samples from first-onset drug-naive SCZ patients in comparison to 
33 controls19. These proteins were adapted into a DiscoveryMAP mul-
tiplex immunoassay platform (Myriad Genetics) leading to a blood 
test capable of distinguishing drug-naïve SCZ patients from controls. 
This test has been marketed under the trade name VeriPsychTM only 
in USA and according to the manufactures “…it is not intended to 
provide a definitive diagnosis of schizophrenia, or to be used as the 
sole means of patient treatment” but used as an aid to the diagnosis 
(http://www.veripsych.com/about).
In a targeted proteomic study of 66 SCZ patients compared 
to 68 controls, increased levels of circulating levels of proinsulin, 
des-31,32-proinsulin, insulin, connecting (C)-peptide and chromo-
granin A were observed20. The same research group found increased 
levels of insulin, chromogranin A pancreatic polypeptide, prolactin, 
progesterone and cortisol in the serum of 236 SCZ subjects compared 
to 230 controls as well as decreased levels of growth hormone. Both 
studies support the metabolic and HPA axis dysfunction in SCZ21. 
Conclusions 
Proteomic studies in brain tissue aimed to reveal protein biomar-
kers which could have a diagnostic potential so as drug treatment 
response and prognostic biomarkers. Although several potential 
biomarkers candidates22 were revealed in several brain regions, 
these could not be directly translated to peripheral tissue for cli-
nical use. On the other hand, data resulting from these analyses 
could shed light in the comprehension of SCZ. For instance, whilst 
energy metabolism dysfunction was known in SCZ brain, proteomic 
studies could pinpointing the exact enzymes and pathways mostly 
involved in the disease. Similarly, protein expression differences of 
cytoskeleton proteins were also characterized. Impairments in oligo-
dendrocytes metabolism could also be supported by proteomics in 
brain tissue, also suggesting the pivotal role of glia in SCZ, as it has 
been hypothesized23. Studies in the SCZ CSF revealed more tangible 
biomarkers, but the sampling is much more invasive and painful 
then blood serum, on which successful results could have been 
obtained. Serum analyses have led to the development of a product 
that helps diagnosis. Although this test is not a definitive product, 
the same strategy can be applied for studies of drug response and 
effectiveness. Next steps include following up the protein markers 
found on those proteomic studies. About SCZ pathobiology, func-
tional studies involving knock-outs and overexpression of certain 
protein targets may decipher their role in preclinical models. From 
the biomarker point of view, follow up studies must aim turning 
basic findings in clinical applications. Patient stratification studies 
and characterization of drug response are needed. 
Proteomics methodologies
Since proteomics aims for complete representation of a set of proteins 
expressed by a cell, tissue, or organism on a given time at a given 
condition, it is important that such analysis can reach the most 
complete visualization of the proteins in such contexts24.
The main steps of a proteomic analysis include protein extraction, 
separation, identification and, in most cases, a quantitative analysis. 
It is important to highlight that not all extracted proteins are identi-
fied. Generally, there are groups of proteins such as extremely acidic 
or basic proteins as well as very large or small and hydrophobic 
proteins which are less represented due to their physicochemical 
characteristics, even if they are present at significant amounts in the 
analyzed cell, tissue or organism. Besides, the proteome of a given 
cell present oligarchic characteristic considering the wide dynamic 
range of proteins concentration. Therefore, in order to reach the 
most complete proteome visualization, the step of protein extrac-
tion becomes a critical component in any proteomic analysis, since 
it is necessary to extract as more proteins as possible. An interes-
ting approach for sample preparation is to extract subproteomes 
by separating sets of proteins according to their characteristics or 
cellular localization enabling better resolution. There are several 
different extraction methods25, each one presenting weaknesses and 
strengths. Thus, their combination may generate a wider coverage 
of the proteome of interest.
The next step is the fractionation of the extract proteins. These 
can be classified in general as “in gel” or “off gel” fractionation. The 
main in gel approach for proteomics is two-dimensional electropho-
resis (2-DE). In principle, proteins are separated firstly according to 
their isoelectric point (pI) followed by an SDS-PAGE step on which 
are separated according to their molecular mass (MW). The result is 
a Cartesian plot on which the “x” axis represents the pI and the “y” 
axis represents the molecular masses of the proteins. Each one of the 
dots of this plot – the so called spots – represents, in theory, different 
proteins. Resultant gels can be stained post-electrophoresis by classi-
cal protocols such as coomassie blue or silver staining. An alternative 
technique is the two-dimensional differential gel electrophoresis 
(2D-DIGE) on which protein samples are labeled with fluorescent 
dyes and mixed prior 2-DE. Only one gel is needed and proteins can 
be observed and quantified using a fluorescence scanner. Specific 
computational programs for image analysis perform densitometry 
measurement, allowing relative quantification of protein spots and 
comparison among different gels. Spots found significantly different 
among compared samples can be excised from the gel and processed 
for further analyses. The protein identification is performed by mass 
spectrometry (MS) using a methodology named “peptide mass fin-
gerprinting” (PMF). Here, after spot digestion with a defined protease, 
molecular masses from the resulting peptides are obtained by MS. 
These masses are compared to theoretical masses obtained by in silico 
digestion of the whole translated genome of interest, leading to the 
protein identification. Drawbacks of the combination 2-DE/MS are 
the existing variation among different gels – which are reduced us-
ing 2D-DIGE, since different samples can be compared on a single 
gel – the representation of extremely acidic and basic proteins as well 
as hydrophobic proteins. 
Off-gel approaches are a milestone on proteomics since data 
acquisition throughput, sensitivity and accuracy have improved 
significantly and several drawbacks associated to 2-DE were over-
come. The main principle of “shotgun proteomics”26 is to digest 
the whole proteome of interest before separation. Peptides are then 
separated by liquid chromatography and usually eluted online into a 
mass hybrid spectrometer (LC-MS/MS). Depending on the sample 
complexity steps of pre-fractionation before LC-MS may be needed. 
Pre-fractionation methods can be other types of chromatography, 
isoelectric focusing or in-gel electrophoresis. Protein identification 
relies strongly on computational resources that combine and interpret 
data generated by MS/MS. 
Quantification can be performed by different methods. Stable 
isotopes labeling in vitro such as ICAT27, and ICPL28 allow the 
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comparison from two to four samples. Prior to LC-MS/MS, pro-
tein or peptide of each sample are labeled with two to four stable 
isotopes – so called tags. The tags are chemically identical, but may 
carry different combination of heavy isotopes, usually 2H, 13C or 
15N. Since the mass of the tags are known, it is possible to identify 
by MS labeled peptides, allowing the identification of peptides. 
The relative quantification is performed by comparing the peak 
intensities of each peptide labeled with different tags. Another 
quantitative methodology which has been used on psychiatric 
proteomic research is the isobaric tags for relative and absolute 
quantification – iTRAQ29 which allows the quantification of up to 
eight samples at once. iTRAQ tags are composed by three parts: a 
reactive site, a balance region (BR) and the reporter ion (RI). BR 
and RI of each tag have different masses which are complementary 
in order to make all tags isobaric. Thus, the same peptides species 
from different samples present the same molecular mass even when 
labeled with different tags. But once submitted to MS/MS, the BR is 
lost and each RI will present its different mass, providing data for 
relative quantitation through the analysis of their intensities. The 
disadvantage of methods utilizing such labels is that the labeling 
procedure occurs after sample extraction and preparation, what 
can lead to the insertion of technical errors and loss of accuracy 
on quantification procedure. In vivo labeling is also an alternative 
as discuss in the article of Dr. M. Filiou, in this same edition. An-
other well characterized in vivo labeling approach is SILAC (stable 
isotope labeling by amino acids in cell culture)30. Here, cell culture 
is grown on a media with heavy aminoacids – preferably lysine and 
arginine to do the large use of trypsin as enzyme in proteomics. 
This allows the comparison to cells grown in non-labeled media. 
SILAC can also be applied in animal models. Alternatively, shotgun 
proteomic data can be analyzed using label-free quantification. This 
technique is based on the fact that the concentration of a certain 
peptide of a given sample is directly proportional to its peak chro-
matographic area31. Based on this principle, it is possible to analyze 
an unlimited number of samples what is suitable for clinical and 
biomarker studies. 
Not all proteomic methods are explored by psychiatric research. 
For instance, not so much has been done using large-scale studies of 
protein post translational modification as well as targeted analyses as 
selected/multiple reaction monitoring (SRM/MRM). The proteomic 
toolbox may still provide more solutions and answers to psychiatric 
studies25. 
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